Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The REmission of the Impulse Control Disorder and the Changes of the Neuropsychiatric Characteristics After Switching Into Levodopa/Carbidopa in Patients With Parkinson's Disease Who Have Developed Impulse Control Disorders Due to the Dopamine Replacement Therapy

NCT01683253 is registered in ClinicalTrials.gov with Sandoz as lead sponsor.

NCT NCT01683253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01683253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The REmission of the Impulse Control Disorder and the Changes of the Neuropsychiatric Characteristics After Switching Into Levodopa/Carbidopa in Patients With Parkinson's Disease Who Have Developed Impulse Control Disorders Due to the Dopamine Replacement Therapy
Lead sponsor
Sandoz
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2012
Completion date
December 31, 2014
Enrollment
150 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

impulse control disorder